| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.21 | 3e-05 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0002 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.19 | 0.0004 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.17 | 0.0004 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.17 | 0.0008 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.093 | 0.002 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.35 | 0.002 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.003 |